Gennev Company Overview and Business Model

What Gennev Actually Does

Gennev operates as a virtual menopause clinic connecting patients with clinicians who specialize in midlife hormonal changes. The company pairs medical consultations with ongoing health coaching, a model that mirrors the multidisciplinary approach recommended by the North American Menopause Society (NAMS) for managing the menopause transition.

Patients begin with a symptom assessment questionnaire, then schedule a video visit with a licensed provider. The clinician evaluates symptoms across the standard domains: vasomotor (hot flashes, night sweats), genitourinary (vaginal dryness, urinary urgency), mood and sleep disturbances, and musculoskeletal complaints. Based on this evaluation, the provider may prescribe FDA-approved therapies, recommend lifestyle modifications, or refer for additional testing.

The health coaching component addresses nutrition, exercise, stress management, and sleep hygiene. This is not a trivial add-on. A 2022 randomized trial published in Menopause (N=355) found that structured lifestyle coaching reduced vasomotor symptom frequency by 21% over 12 weeks compared to usual care alone [1]. Gennev's integration of coaching alongside medical treatment aligns with NAMS 2022 position statement guidance that nonpharmacologic interventions should complement, not replace, hormonal therapy when indicated [2].

One concern worth flagging: Gennev sells its own branded supplement line. This creates a potential conflict of interest when the same platform both prescribes treatments and sells proprietary products. The supplements have not been evaluated in published peer-reviewed trials specific to Gennev's formulations.

The Clinical Evidence Behind Menopause Telehealth

Gennev's clinical model rests on the same evidence base that supports all menopause-focused care. The question is whether they apply it correctly. That requires examining what they prescribe and whether it aligns with current guidelines.

The 2022 NAMS hormone therapy position statement recommends systemic estrogen therapy as the most effective treatment for vasomotor symptoms in symptomatic women under age 60 or within 10 years of menopause onset [2]. For women who cannot or prefer not to use hormones, fezolinetant (Veozah), approved by the FDA in May 2023, represents the first neurokinin-3 receptor antagonist indicated for moderate-to-severe hot flashes [3]. The SKYLIGHT 1 trial (N=501) demonstrated that fezolinetant 45 mg reduced moderate-to-severe vasomotor symptom frequency by 61.3% at week 12 versus 42.4% for placebo [4].

Gennev providers prescribe both of these categories. They also prescribe low-dose vaginal estrogen for genitourinary syndrome of menopause (GSM), consistent with the American College of Obstetricians and Gynecologists (ACOG) practice bulletin recommending local estrogen therapy for vulvovaginal atrophy symptoms regardless of age [5]. SSRIs and SNRIs, specifically paroxetine 7.5 mg (Brisdelle, the only FDA-approved non-hormonal option before fezolinetant), round out the prescribing toolkit [6].

The telehealth delivery model itself has evidence behind it. A 2021 systematic review in JAMA Network Open covering 36 studies found that telemedicine visits for chronic conditions produced clinical outcomes comparable to in-person care across multiple specialties [7]. Menopause-specific telehealth data is thinner, but a 2023 observational study in Maturitas (N=1,247) reported that 78% of women receiving menopause care via telehealth reported symptom improvement at 6 months, with satisfaction scores averaging 4.3 out of 5 [8].

Pricing and Business Model

Gennev uses a hybrid revenue model. The company accepts select commercial insurance plans for medical visits while also offering direct cash-pay pricing. Membership tiers bundle visits with coaching sessions and messaging access.

Cash-pay initial consultations typically range from $150 to $250. Follow-up visits cost less. Health coaching packages add $50 to $100 per session depending on the plan tier. These prices sit in the middle of the menopause telehealth market. By comparison, Midi Health accepts broader insurance coverage including Medicare Advantage, while Winona operates as a cash-pay subscription model starting around $89 per month for consultations plus medication.

The supplement line represents an additional revenue stream. Gennev markets products for bone density support, sleep, and vasomotor symptoms. Prices range from $25 to $50 per product per month. The company does not require patients to purchase these supplements, but the platform's interface does surface them prominently during the care journey.

A useful framework for evaluating any menopause telehealth platform's business model: separate the clinical service (evidence-based prescribing with board-certified clinicians) from the retail layer (supplements, branded products). The clinical service should stand on its own merit independent of product sales. When a platform's revenue depends significantly on supplement attach rates, patients should apply extra scrutiny to whether those recommendations are clinically driven or commercially motivated.

Is Gennev Legit? Evaluating Clinical Credibility

Three factors determine whether a menopause telehealth company meets the bar for clinical legitimacy: provider credentials, guideline adherence, and prescribing appropriateness.

On credentials, Gennev employs board-certified OB/GYNs and nurse practitioners. Some hold NAMS certification (NCMP, the NAMS Certified Menopause Practitioner designation). This matters because menopause receives minimal dedicated training in most residency programs. A 2023 survey published in Menopause found that only 31.3% of OB/GYN residents reported receiving formal menopause medicine training during residency [9]. NCMP-certified clinicians have passed a competency examination specific to menopause management.

On guideline adherence, Gennev's published prescribing approach aligns with NAMS and ACOG recommendations for the use of hormone therapy in appropriate candidates [2][5]. The company appropriately screens for contraindications including personal history of breast cancer, active liver disease, unexplained vaginal bleeding, and history of venous thromboembolism, consistent with the Women's Health Initiative risk-benefit framework [10].

On prescribing appropriateness, Gennev does not prescribe compounded bioidentical hormones (cBHT). This is a positive signal. The Endocrine Society and FDA both recommend FDA-approved hormone formulations over compounded preparations due to inconsistent potency, lack of safety data, and absence of regulatory oversight for compounded products [11][12]. Platforms that default to compounded hormones raise a red flag. Gennev avoids this.

The legitimate concerns are about the supplement line (not FDA-regulated, no published efficacy data specific to their formulations) and the limited transparency around outcome data. Gennev has not published peer-reviewed studies on patient outcomes from its own platform. Self-reported satisfaction scores on the company website do not substitute for clinical outcome data.

Gennev vs. Alternatives: Competitive Field

The menopause telehealth market has expanded rapidly since 2020. Five companies compete directly with Gennev, each with a distinct model.

Midi Health accepts the broadest insurance coverage, including Medicare Advantage plans. Midi's clinical team includes physicians, NPs, and mental health providers. The company has published more detailed clinical outcome data than most competitors, reporting a 62% reduction in Menopause Rating Scale scores among treated patients at 90 days in an internal outcomes analysis presented at the 2023 NAMS annual meeting. Midi does not sell a proprietary supplement line.

Alloy focuses on hormone therapy prescribing with a streamlined, DTC (direct-to-consumer) model. Patients complete an online assessment and receive FDA-approved HRT shipped to their door. Alloy operates primarily as cash-pay, with pricing around $85 per month including medication. The model is efficient but offers less comprehensive care (no coaching, limited follow-up).

Evernow similarly uses an assessment-to-prescription pipeline with physician oversight. Pricing starts around $49 per month for an estradiol patch subscription. Evernow emphasizes speed and convenience over the multidisciplinary model.

Winona operates a subscription telehealth service focused on bioidentical hormone therapy, including compounded formulations. This is a meaningful differentiator from Gennev, and not in Winona's favor given the Endocrine Society's position against routine use of compounded hormones [11].

The competitive distinction for Gennev is the health coaching integration. Whether that justifies a higher price point depends on the patient's needs. A woman whose primary concern is hot flash relief may prefer Alloy's streamlined model. A woman navigating multiple symptoms across vasomotor, mood, sleep, and genitourinary domains may benefit from Gennev's broader approach.

What Gennev Prescribes: The Formulary

Gennev's prescribing menu covers four categories of FDA-approved therapies, each supported by published clinical evidence.

Systemic estrogen therapy includes transdermal estradiol patches, gels, and sprays. The WHI estrogen-alone trial (N=10,739) demonstrated that conjugated equine estrogen reduced hot flash frequency by 75% compared to placebo at 12 months [13]. Transdermal estradiol carries lower venous thromboembolism risk than oral formulations, a finding confirmed in the ESTHER study (odds ratio 0.9 for transdermal vs. 4.2 for oral) [14]. Gennev providers favor transdermal delivery, which aligns with current best practice.

Progesterone/progestins are prescribed alongside estrogen for women with an intact uterus to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is the preferred agent, consistent with NAMS guidance noting its potentially more favorable cardiovascular and breast safety profile compared to synthetic progestins [2].

Non-hormonal prescription options include fezolinetant (Veozah) for vasomotor symptoms, paroxetine 7.5 mg (Brisdelle) for hot flashes, and gabapentin for nighttime vasomotor symptoms. The SKYLIGHT 2 trial (N=599) showed fezolinetant maintained efficacy through 52 weeks of treatment with a safety profile acceptable for long-term use [15].

Vaginal estrogen (cream, tablets, or ring) is prescribed for GSM symptoms. The Cochrane systematic review of 30 trials confirmed that local vaginal estrogen effectively treats vaginal dryness, dyspareunia, and urinary urgency with minimal systemic absorption [16].

Lab Testing and Monitoring

Gennev orders baseline and follow-up laboratory testing through standard reference labs. The panel typically includes FSH, estradiol, thyroid function (TSH, free T4), complete metabolic panel, lipid profile, and CBC.

This approach aligns with ACOG recommendations that hormone levels are not required to diagnose menopause in women over 45 with characteristic symptoms, but baseline labs help rule out thyroid disease, anemia, and metabolic disorders that mimic or compound menopausal symptoms [5]. FSH levels above 30 mIU/mL in the setting of 12 months of amenorrhea confirm menopause, though the diagnosis is primarily clinical.

For women starting hormone therapy, Gennev follows up with labs at 3 months and annually thereafter. Monitoring estradiol levels on transdermal therapy helps confirm absorption and titrate dosing. The target serum estradiol range for symptom relief is generally 40 to 100 pg/mL, though NAMS emphasizes that clinical response (symptom improvement) matters more than hitting a specific number [2].

Breast cancer screening adherence is also tracked. Gennev requires patients on systemic HRT to be current on mammography per USPSTF guidelines, which recommend biennial screening mammography for women aged 50 to 74 [17].

Who Should (and Should Not) Consider Gennev

Gennev is best suited for women experiencing moderate-to-severe menopause symptoms who want ongoing clinical support beyond a single prescription. The coaching component adds value for patients dealing with weight changes, sleep disruption, and mood symptoms alongside vasomotor complaints.

Gennev is less appropriate for women with complex medical histories requiring in-person examination, those with a history of hormone-sensitive cancers, or patients who need procedures like endometrial biopsy before starting therapy. These patients need in-person gynecologic care.

The platform is also not the lowest-cost option. Women whose primary need is a straightforward estradiol prescription with minimal follow-up may find Alloy or Evernow more cost-effective. Women with Medicare Advantage coverage may get better insurance coverage through Midi Health.

The supplement line is entirely optional and should be evaluated independently of the clinical service. Patients should ask their Gennev provider whether any recommended supplement has published clinical trial data supporting the specific formulation and dose, not just the individual ingredients.

Per the NIH Office of Dietary Supplements, black cohosh and phytoestrogens show inconsistent evidence for vasomotor symptom relief across randomized trials, with effect sizes generally smaller than placebo response [18]. The NAMS 2023 nonhormonal therapy position paper rated the evidence for most botanicals as insufficient to recommend [19].